Deciphera Pharmaceuticals, Inc. Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 31 rows in 2018. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2018-09-20: Reporting owner Morl Christopher John; Form 3; Security Stock Option (Right to Buy); Transaction Holding.
- 2018-09-20: Reporting owner Morl Christopher John; Form 3; Security Stock Option (Right to Buy); Transaction Holding.
- 2018-09-20: Reporting owner Morl Christopher John; Form 3; Security Stock Option (Right to Buy); Transaction Holding.
- 2018-09-20: Reporting owner Flynn Daniel Lee; Form 3; Security Stock Option (Right to Buy); Transaction Holding.
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2018-09-20 holding as of filing | Morl Christopher John Officer (Chief Business Officer) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $3.95 exercise price | 2018-09-20 | ||
| 2018-09-20 holding as of filing | Morl Christopher John Officer (Chief Business Officer) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $6.13 exercise price | 2018-09-20 | ||
| 2018-09-20 holding as of filing | Morl Christopher John Officer (Chief Business Officer) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $17.00 exercise price | 2018-09-20 | ||
| 2018-09-20 holding as of filing | Flynn Daniel Lee Officer (Chief Scientific Officer) | 3 | Stock Option (Right to Buy) Derivative · Direct · (m) | Holding | $1.89 exercise price | 2018-09-20 | ||
| 2018-09-20 holding as of filing | Flynn Daniel Lee Officer (Chief Scientific Officer) | 3 | Stock Option (Right to Buy) Derivative · Direct · (m) | Holding | $1.89 exercise price | 2018-09-20 | ||
| 2018-09-20 holding as of filing | Flynn Daniel Lee Officer (Chief Scientific Officer) | 3 | Stock Option (Right to Buy) Derivative · Direct · (m) | Holding | $3.95 exercise price | 2018-09-20 | ||
| 2018-09-20 holding as of filing | Flynn Daniel Lee Officer (Chief Scientific Officer) | 3 | Stock Option (Right to Buy) Derivative · Direct · (m) | Holding | $6.13 exercise price | 2018-09-20 | ||
| 2018-09-20 holding as of filing | Rosen Oliver Officer (Chief Medical Officer) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $1.89 exercise price | 2018-09-20 | ||
| 2018-09-20 holding as of filing | Rosen Oliver Officer (Chief Medical Officer) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $1.89 exercise price | 2018-09-20 | ||
| 2018-09-20 holding as of filing | Rosen Oliver Officer (Chief Medical Officer) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $3.95 exercise price | 2018-09-20 | ||
| 2018-09-20 holding as of filing | Rosen Oliver Officer (Chief Medical Officer) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $6.13 exercise price | 2018-09-20 | ||
| 2018-09-18 | Martin Daniel C. Officer (Chief Commercial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +90,000 90,000 owned after | $36.10 exercise price | 2018-09-20 | |
| 2018-05-29 | Ruddy Stephen B. Officer (Chief Technical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +90,000 90,000 owned after | $26.50 exercise price | 2018-09-20 | |
| 2018-05-17 | Ross Michael Jay Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +12,000 12,000 owned after | $25.73 exercise price | 2018-05-21 | |
| 2018-05-17 | Ratcliffe Liam Director, 10% Owner | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +12,000 12,000 owned after | $25.73 exercise price | 2018-05-21 | |
| 2018-05-17 | Hoerter Steven L. Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +24,000 24,000 owned after | $25.73 exercise price | 2018-05-21 | |
| 2018-05-17 | Allen Patricia L Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +12,000 12,000 owned after | $25.73 exercise price | 2018-05-21 | |
| 2018-05-17 | Martin John Richard Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +12,000 12,000 owned after | $25.73 exercise price | 2018-05-21 | |
| 2018-05-17 | Bristol James Arthur Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +12,000 12,000 owned after | $25.73 exercise price | 2018-05-21 | |
| 2018-05-17 | Benz Edward J. JR Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +12,000 12,000 owned after | $25.73 exercise price | 2018-05-21 | |
| 2018-05-17 | Walsh Dennis Leo Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +12,000 12,000 owned after | $25.73 exercise price | 2018-05-21 | |
| 2018-03-28 holding as of filing | Ross Michael Jay Director | 3/A | Stock Option (Right to Buy) Derivative · Direct | Holding | $17.00 exercise price | 2018-03-28 | ||
| 2018-03-28 holding as of filing | Ratcliffe Liam Director, 10% Owner | 3/A | Stock Option (Right to Buy) Derivative · Direct | Holding | $17.00 exercise price | 2018-03-28 | ||
| 2018-03-28 holding as of filing | Walsh Dennis Leo Director | 3/A | Stock Option (Right to Buy) Derivative · Direct | Holding | $17.00 exercise price | 2018-03-28 | ||
| 2018-03-28 holding as of filing | Martin John Richard Director | 3/A | Stock Option (Right to Buy) Derivative · Direct | Holding | $17.00 exercise price | 2018-03-28 | ||
| 2018-02-16 | Rosen Oliver Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +68,500 68,500 owned after | $29.71 exercise price | 2018-09-20 | |
| 2018-02-16 | Flynn Daniel Lee Officer (Chief Scientific Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct · (m) | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +68,500 68,500 owned after | $29.71 exercise price | 2018-09-20 | |
| 2018-02-16 | Morl Christopher John Officer (Chief Business Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +60,000 60,000 owned after | $29.71 exercise price | 2018-09-20 | |
| 2018-02-16 | Kelly Thomas Patrick Officer (Chief Financial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +90,000 90,000 owned after | $29.71 exercise price | 2018-02-20 | |
| 2018-02-16 | Taylor Michael Douglas Director, Officer (See Remarks) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +225,000 225,000 owned after | $29.71 exercise price | 2018-02-20 | |
| 2018-01-30 | Morl Christopher John Officer (Chief Business Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +52,000 52,000 owned after | $26.35 exercise price | 2019-02-01 |